|75.83||+0.7900||+1.05%||Vol 1.77M||1Y Perf 8.82%|
|Aug 2nd, 2021 16:00 DELAYED|
|- -%||- -|
|Target Price||83.27||Analyst Rating||Moderate Buy 2.00|
|Potential %||9.81||Finscreener Ranking||★★★★ 53.65|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★ 55.81|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 68.45|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||19.22B||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||67.47||Earnings Date||28th Jul 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||1.11|
|EPS Growth Next 5 Years %||15.00|
|Avg. Weekly Volume||2.63M|
|Avg. Monthly Volume||2.21M|
|Avg. Quarterly Volume||2.49M|
Hologic Inc. (NASDAQ: HOLX) stock closed at 75.83 per share at the end of the most recent trading day (a 1.05% change compared to the prior day closing price) with a volume of 1.78M shares and market capitalization of 19.22B. Is a component of S&P 500, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 5814 people. Hologic Inc. CEO is Stephen P. Macmillan.
The one-year performance of Hologic Inc. stock is 8.82%, while year-to-date (YTD) performance is 4.12%. HOLX stock has a five-year performance of 94.44%. Its 52-week range is between 56.81 and 85, which gives HOLX stock a 52-week price range ratio of 67.47%
Hologic Inc. currently has a PE ratio of 9.60, a price-to-book (PB) ratio of 4.91, a price-to-sale (PS) ratio of 3.39, a price to cashflow ratio of 8.50, a PEG ratio of 2.32, a ROA of 25.84%, a ROC of 33.56% and a ROE of 65.13%. The company’s profit margin is 36.11%, its EBITDA margin is 53.80%, and its revenue ttm is $5.66 Billion , which makes it $22.34 revenue per share.
Of the last four earnings reports from Hologic Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $1.11 for the next earnings report. Hologic Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Hologic Inc. is Moderate Buy (2), with a target price of $83.27, which is +9.81% compared to the current price. The earnings rating for Hologic Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Hologic Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Hologic Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.40, ATR14 : 1.59, CCI20 : 180.44, Chaikin Money Flow : 0.12, MACD : 2.16, Money Flow Index : 73.29, ROC : 10.91, RSI : 76.92, STOCH (14,3) : 93.57, STOCH RSI : 1.00, UO : 56.07, Williams %R : -6.43), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Hologic Inc. in the last 12-months were: Allison P. Bebo (Sold 6 100 shares of value $512 778 ), Benjamin J. Cohn (Option Excercise at a value of $709 146), Benjamin J. Cohn (Sold 26 339 shares of value $1 992 182 ), Christiana Stamoulis (Option Excercise at a value of $249 113), Christiana Stamoulis (Sold 11 146 shares of value $824 804 ), John M. Griffin (Option Excercise at a value of $915 084), John M. Griffin (Sold 22 900 shares of value $1 627 689 ), Karleen M. Oberton (Option Excercise at a value of $536 283), Karleen M. Oberton (Sold 15 000 shares of value $937 500 ), Kevin R. Thornal (Option Excercise at a value of $652 658), Kevin R. Thornal (Sold 16 869 shares of value $1 248 212 ), Scott T. Garrett (Option Excercise at a value of $249 113), Sean S. Daugherty (Sold 4 001 shares of value $260 149 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.